news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

risk warning factors have been eliminated, and many a-share listed companies have "taken off the st label". according to choice data, 8 st companies have successfully "taken off the st label" in the second half of the year.the specific a-share list mainly includes hekeda, oride, wanlin logistics, xining special steel, quanzhu shares, mogao shares, kangmei pharmaceutical and quanxinhaothe specific situation is as follows:

hekoda, whose main business is the research and development, design, production and sales of precision cleaning equipment and water treatment equipment, announced on september 6 that the company's stock trading will be suspended for one day on september 9, 2024 (monday) and will resume trading from the opening of the market on september 10, 2024 (tuesday);the company's stock trading will remove the "delisting risk warning" from the opening of the market on september 10, 2024. after "removing the star hat", hekoda closed on thursday and won three consecutive boardson september 11, hekoda issued an unusual announcement. although the company has opened up new business growth points, it may still face multiple uncertainties in actual operations, such as changes in industry policies, intensified market competition, and operational management challenges. there is a certain degree of uncertainty in business development. hekoda stated on the interactive platform on september 11 that the company has made strategic layout and investment in the field of intelligent equipment wiring harnesses in 2023, aiming to open up new business growth points.at the same time, we will gradually strengthen the technical research and self-production capabilities of core components, and achieved operating income of rmb 14.0759 million in the first half of 2024, achieving certain results.

xining special steel, which mainly engages in the smelting and rolling processing of special steel, announced on july 16 that the company's stock will be suspended for one day from the opening of the market on july 17, and will resume trading from the opening of the market on july 18;the company's stock has been cleared of other risk warnings since the opening of the market on july 18. after the "hat" was removed, xining special steel closed at the daily limit on july 18.xining special steel released its semi-annual report on august 29, with a net loss of 294 million yuan attributable to the parent company's owners in the first half of the year, compared with a net loss of 1.057 billion yuan in the same period last year, and the loss narrowed. xining special steel also disclosed thatthe company is the largest special steel production base in western chinait is a national innovative enterprise and a national important equipment supporting enterprise. it has formed a steel enterprise with an annual comprehensive production capacity of 2.1 million tons of steel and 2 million tons of steel products.

kangmei pharmaceutical, which mainly produces and sells chinese herbal medicines and chemical drugs, announced on july 2 that the company's stock will be suspended for one day on july 3.the stock was resumed on july 4 and other risk warnings were revoked. after the delisting, kangmei pharmaceutical closed at the daily limit on july 4.kangmei pharmaceutical released its semi-annual report on august 23, with a net profit attributable to the parent company's owners of 15.7603 million yuan in the first half of the year, compared with a net loss of 126 million yuan in the same period last year, turning losses into profits. kangmei pharmaceutical said on the interactive platform on august 30 that the company will continue to promote the implementation of the "12355" strategic plan, based on the strategic positioning of a smart chinese medicine health brand enterprise with chinese herbal medicine pieces as the core.focusing on the two strategic themes of "building a full-chain characteristic industry of chinese herbal medicine pieces" and "providing special medical and health services", with five major business segments including traditional chinese medicine, medical health care, chinese medicine city, health products and pharmaceutical commerce as the main body, we will innovate business formats and business growth models, and optimize and adjust the layout of regional industrial clusters.

quanxinhao announced on june 30 that the company's stock trading will be suspended for one day on july 1, 2024, and will resume trading at the opening of the market on july 2, 2024.the company will remove the delisting risk warning from the opening of the market on july 2, 2024. after "taking off the star hat", xinxinhao closed at the daily limit on july 2.on august 30, quanxinhao announced its 2024 semi-annual report. during the reporting period, the company's operating income was 78.5303 million yuan, a year-on-year decrease of 24.38%; the net profit attributable to shareholders of the listed company was 3.0960 million yuan, a year-on-year decrease of 74.49%. quanxinhao also disclosed that the company made full use of existing resources to explore business diversification. both the big health industry and the automobile industry are industries supported by national policies.subsidiary zero health has the authorization of the world patent technology of japan's eleten co., ltd. and has expanded its health business through the acquisition of jiangmen duhethe subsidiary xincheng ford has obtained authorization from shanghai general motors corporation and has integrated its advantages through the extensive industry sales experience and high-quality customer resources of its partner yancheng xincheng automobile sales and service co., ltd. currently, the above-mentioned businesses are being carried out stably.